|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GLUL |
Gene summary for GLUL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GLUL | Gene ID | 2752 |
| Gene name | glutamate-ammonia ligase | |
| Gene Alias | GLNS | |
| Cytomap | 1q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | A8YXX4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2752 | GLUL | GSM4909285 | Human | Breast | IDC | 1.88e-07 | 6.24e-02 | 0.21 |
| 2752 | GLUL | GSM4909286 | Human | Breast | IDC | 9.17e-06 | -1.86e-01 | 0.1081 |
| 2752 | GLUL | GSM4909293 | Human | Breast | IDC | 1.66e-05 | 1.19e-01 | 0.1581 |
| 2752 | GLUL | GSM4909296 | Human | Breast | IDC | 3.25e-03 | -4.65e-02 | 0.1524 |
| 2752 | GLUL | GSM4909297 | Human | Breast | IDC | 6.94e-05 | -1.59e-01 | 0.1517 |
| 2752 | GLUL | GSM4909298 | Human | Breast | IDC | 2.86e-12 | 3.96e-01 | 0.1551 |
| 2752 | GLUL | GSM4909302 | Human | Breast | IDC | 7.86e-29 | 6.93e-01 | 0.1545 |
| 2752 | GLUL | GSM4909304 | Human | Breast | IDC | 1.06e-50 | 8.71e-01 | 0.1636 |
| 2752 | GLUL | GSM4909305 | Human | Breast | IDC | 1.24e-10 | 4.62e-01 | 0.0436 |
| 2752 | GLUL | GSM4909306 | Human | Breast | IDC | 1.90e-08 | 4.09e-01 | 0.1564 |
| 2752 | GLUL | GSM4909308 | Human | Breast | IDC | 1.08e-15 | 4.41e-01 | 0.158 |
| 2752 | GLUL | GSM4909311 | Human | Breast | IDC | 5.17e-27 | 9.98e-02 | 0.1534 |
| 2752 | GLUL | GSM4909312 | Human | Breast | IDC | 1.29e-40 | 7.37e-01 | 0.1552 |
| 2752 | GLUL | GSM4909313 | Human | Breast | IDC | 1.15e-22 | 7.02e-01 | 0.0391 |
| 2752 | GLUL | GSM4909317 | Human | Breast | IDC | 6.80e-05 | 3.31e-01 | 0.1355 |
| 2752 | GLUL | GSM4909319 | Human | Breast | IDC | 8.88e-28 | -1.12e-01 | 0.1563 |
| 2752 | GLUL | GSM4909321 | Human | Breast | IDC | 3.35e-16 | 3.13e-01 | 0.1559 |
| 2752 | GLUL | brca2 | Human | Breast | Precancer | 2.74e-16 | 4.97e-01 | -0.024 |
| 2752 | GLUL | brca3 | Human | Breast | Precancer | 1.73e-04 | 2.81e-01 | -0.0263 |
| 2752 | GLUL | M2 | Human | Breast | IDC | 2.60e-13 | 7.34e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003450410 | Prostate | BPH | protein localization to nucleus | 98/3107 | 290/18723 | 4.78e-13 | 4.35e-11 | 98 |
| GO:007149618 | Prostate | BPH | cellular response to external stimulus | 102/3107 | 320/18723 | 8.99e-12 | 6.79e-10 | 102 |
| GO:190495117 | Prostate | BPH | positive regulation of establishment of protein localization | 101/3107 | 319/18723 | 1.77e-11 | 1.24e-09 | 101 |
| GO:190018010 | Prostate | BPH | regulation of protein localization to nucleus | 54/3107 | 136/18723 | 1.02e-10 | 6.02e-09 | 54 |
| GO:005122217 | Prostate | BPH | positive regulation of protein transport | 93/3107 | 303/18723 | 6.94e-10 | 3.25e-08 | 93 |
| GO:003166817 | Prostate | BPH | cellular response to extracellular stimulus | 79/3107 | 246/18723 | 1.32e-09 | 5.69e-08 | 79 |
| GO:009013216 | Prostate | BPH | epithelium migration | 104/3107 | 360/18723 | 2.96e-09 | 1.15e-07 | 104 |
| GO:009013016 | Prostate | BPH | tissue migration | 105/3107 | 365/18723 | 3.21e-09 | 1.24e-07 | 105 |
| GO:001063116 | Prostate | BPH | epithelial cell migration | 103/3107 | 357/18723 | 3.80e-09 | 1.44e-07 | 103 |
| GO:004225418 | Prostate | BPH | ribosome biogenesis | 90/3107 | 299/18723 | 3.82e-09 | 1.44e-07 | 90 |
| GO:000166717 | Prostate | BPH | ameboidal-type cell migration | 128/3107 | 475/18723 | 5.69e-09 | 2.05e-07 | 128 |
| GO:001063216 | Prostate | BPH | regulation of epithelial cell migration | 87/3107 | 292/18723 | 1.18e-08 | 3.87e-07 | 87 |
| GO:00506739 | Prostate | BPH | epithelial cell proliferation | 116/3107 | 437/18723 | 7.12e-08 | 1.85e-06 | 116 |
| GO:00506789 | Prostate | BPH | regulation of epithelial cell proliferation | 104/3107 | 381/18723 | 7.52e-08 | 1.92e-06 | 104 |
| GO:003166910 | Prostate | BPH | cellular response to nutrient levels | 67/3107 | 215/18723 | 8.51e-08 | 2.12e-06 | 67 |
| GO:000926710 | Prostate | BPH | cellular response to starvation | 52/3107 | 156/18723 | 2.24e-07 | 4.89e-06 | 52 |
| GO:003166718 | Prostate | BPH | response to nutrient levels | 121/3107 | 474/18723 | 3.68e-07 | 7.70e-06 | 121 |
| GO:004259410 | Prostate | BPH | response to starvation | 59/3107 | 197/18723 | 2.10e-06 | 3.45e-05 | 59 |
| GO:00435429 | Prostate | BPH | endothelial cell migration | 73/3107 | 279/18723 | 3.03e-05 | 3.46e-04 | 73 |
| GO:000974318 | Prostate | BPH | response to carbohydrate | 67/3107 | 253/18723 | 4.20e-05 | 4.48e-04 | 67 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00630 | Colorectum | AD | Glyoxylate and dicarboxylate metabolism | 14/2092 | 30/8465 | 7.25e-03 | 2.97e-02 | 1.89e-02 | 14 |
| hsa01230 | Colorectum | AD | Biosynthesis of amino acids | 28/2092 | 75/8465 | 9.99e-03 | 3.89e-02 | 2.48e-02 | 28 |
| hsa006301 | Colorectum | AD | Glyoxylate and dicarboxylate metabolism | 14/2092 | 30/8465 | 7.25e-03 | 2.97e-02 | 1.89e-02 | 14 |
| hsa012301 | Colorectum | AD | Biosynthesis of amino acids | 28/2092 | 75/8465 | 9.99e-03 | 3.89e-02 | 2.48e-02 | 28 |
| hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa012302 | Colorectum | SER | Biosynthesis of amino acids | 23/1580 | 75/8465 | 8.11e-03 | 4.14e-02 | 3.01e-02 | 23 |
| hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa012303 | Colorectum | SER | Biosynthesis of amino acids | 23/1580 | 75/8465 | 8.11e-03 | 4.14e-02 | 3.01e-02 | 23 |
| hsa006302 | Colorectum | MSI-H | Glyoxylate and dicarboxylate metabolism | 8/797 | 30/8465 | 5.34e-03 | 4.94e-02 | 4.14e-02 | 8 |
| hsa006303 | Colorectum | MSI-H | Glyoxylate and dicarboxylate metabolism | 8/797 | 30/8465 | 5.34e-03 | 4.94e-02 | 4.14e-02 | 8 |
| hsa012306 | Esophagus | HGIN | Biosynthesis of amino acids | 21/1383 | 75/8465 | 7.38e-03 | 4.63e-02 | 3.68e-02 | 21 |
| hsa0123013 | Esophagus | HGIN | Biosynthesis of amino acids | 21/1383 | 75/8465 | 7.38e-03 | 4.63e-02 | 3.68e-02 | 21 |
| hsa0123023 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa006306 | Esophagus | ESCC | Glyoxylate and dicarboxylate metabolism | 21/4205 | 30/8465 | 1.95e-02 | 4.35e-02 | 2.23e-02 | 21 |
| hsa0123033 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
| hsa0063013 | Esophagus | ESCC | Glyoxylate and dicarboxylate metabolism | 21/4205 | 30/8465 | 1.95e-02 | 4.35e-02 | 2.23e-02 | 21 |
| hsa006304 | Liver | Cirrhotic | Glyoxylate and dicarboxylate metabolism | 20/2530 | 30/8465 | 3.36e-05 | 2.54e-04 | 1.57e-04 | 20 |
| hsa012304 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
| hsa0063011 | Liver | Cirrhotic | Glyoxylate and dicarboxylate metabolism | 20/2530 | 30/8465 | 3.36e-05 | 2.54e-04 | 1.57e-04 | 20 |
| hsa0123011 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GLUL | SNV | Missense_Mutation | novel | c.887N>G | p.Asn296Ser | p.N296S | P15104 | protein_coding | deleterious(0.01) | possibly_damaging(0.812) | TCGA-A2-A4S2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
| GLUL | SNV | Missense_Mutation | novel | c.266N>C | p.Phe89Ser | p.F89S | P15104 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
| GLUL | SNV | Missense_Mutation | c.992N>C | p.Gln331Pro | p.Q331P | P15104 | protein_coding | deleterious(0.03) | possibly_damaging(0.609) | TCGA-B6-A0RT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| GLUL | SNV | Missense_Mutation | novel | c.817N>A | p.Ala273Thr | p.A273T | P15104 | protein_coding | deleterious(0) | possibly_damaging(0.879) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
| GLUL | SNV | Missense_Mutation | c.913N>A | p.Glu305Lys | p.E305K | P15104 | protein_coding | deleterious(0.01) | benign(0.218) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| GLUL | SNV | Missense_Mutation | novel | c.1039G>A | p.Asp347Asn | p.D347N | P15104 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| GLUL | SNV | Missense_Mutation | rs753270381 | c.1022N>A | p.Arg341His | p.R341H | P15104 | protein_coding | deleterious(0.02) | benign(0.302) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| GLUL | SNV | Missense_Mutation | c.895C>T | p.Arg299Cys | p.R299C | P15104 | protein_coding | deleterious(0.02) | probably_damaging(0.992) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| GLUL | SNV | Missense_Mutation | c.437C>A | p.Pro146His | p.P146H | P15104 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GLUL | SNV | Missense_Mutation | c.572C>T | p.Ala191Val | p.A191V | P15104 | protein_coding | tolerated(0.11) | benign(0.042) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |